JMP Securities analyst Erik Suppiger reiterates Backblaze (NASDAQ:BLZE) with a Market Outperform and maintains $18 price target.
Merck Announced Five-Year Data for KEYTRUDA Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer
Five-year overall survival rate of 19.4% and 18.4% for KEYTRUDA plus chemotherapy in KEYNOTE-189 and KEYNOTE-407, respectively
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
